← Back to Screener
Vericel Corporation (VCEL)
Price$35.81
Favorite Metrics
Price vs S&P 500 (26W)3.28%
Price vs S&P 500 (4W)4.10%
Market Capitalization$1.81B
P/E Ratio (Annual)109.74x
All Metrics
P/CF (Annual)34.92x
Book Value / Share (Quarterly)$7.01
P/TBV (Annual)5.22x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.89%
Cash Flow / Share (Quarterly)$0.49
Price vs S&P 500 (YTD)-5.05%
Gross Margin (TTM)74.42%
Net Profit Margin (TTM)5.98%
EPS (TTM)$0.26
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$0.26
Revenue Growth (5Y)17.34%
EPS (Annual)$0.32
ROI (Annual)4.63%
Gross Margin (Annual)74.42%
Net Profit Margin (5Y Avg)-1.24%
Cash / Share (Quarterly)$2.72
P/E Basic Excl Extra (TTM)109.74x
Revenue Growth QoQ (YoY)23.27%
EPS Growth (5Y)38.88%
P/E Normalized (Annual)109.74x
ROA (Last FY)3.39%
Revenue Growth TTM (YoY)16.45%
EBITD / Share (TTM)$0.43
ROE (5Y Avg)-1.26%
Operating Margin (TTM)4.00%
Cash Flow / Share (Annual)$0.49
P/B Ratio5.11x
P/B Ratio (Quarterly)5.14x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.21x
Net Interest Coverage (TTM)-1.38x
ROA (TTM)3.67%
EPS Growth QoQ (YoY)23.36%
EV / EBITDA (TTM)76.05x
EPS Incl Extra (Annual)$0.32
Current Ratio (Annual)5.03x
Quick Ratio (Quarterly)4.68x
3-Month Avg Trading Volume0.59M
52-Week Price Return-12.59%
EV / Free Cash Flow (Annual)69.28x
P/E Incl Extra (TTM)109.74x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$6.89
P/S Ratio (Annual)6.56x
Asset Turnover (Annual)0.57x
52-Week High$45.97
Operating Margin (5Y Avg)-2.57%
EPS Excl Extra (Annual)$0.32
CapEx CAGR (5Y)59.51%
Tangible BV CAGR (5Y)78.61%
26-Week Price Return12.03%
Quick Ratio (Annual)4.68x
13-Week Price Return-4.42%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)5.03x
Enterprise Value$1,714.576
Revenue / Share Growth (5Y)15.07%
Asset Turnover (TTM)0.61x
Book Value / Share Growth (5Y)19.03%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)4.05x
Pretax Margin (Annual)6.29%
Cash / Share (Annual)$2.72
3-Month Return Std Dev43.41%
Gross Margin (5Y Avg)70.05%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)36.95%
EBITDA Interim CAGR (5Y)14.38%
ROE (Last FY)4.66%
Net Interest Coverage (Annual)-2.43x
EPS Basic Excl Extra (Annual)$0.32
P/FCF (TTM)56.02x
Receivables Turnover (TTM)3.78x
EV / Free Cash Flow (TTM)69.28x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$0.26
Receivables Turnover (Annual)3.78x
ROI (TTM)5.15%
P/S Ratio (TTM)6.56x
Pretax Margin (5Y Avg)-1.02%
Revenue / Share (Annual)$5.30
Tangible BV / Share (Annual)$6.89
Forward P/E82.42x
Free OCF CAGR (5Y)10.62%
Price vs S&P 500 (52W)-47.69%
P/E Ratio (TTM)109.74x
EPS Growth TTM (YoY)100.99%
Year-to-Date Return-0.92%
5-Day Price Return3.60%
EPS Normalized (Annual)$0.32
ROA (5Y Avg)-0.86%
Net Profit Margin (Annual)5.98%
Month-to-Date Return10.91%
Cash Flow / Share (TTM)$-0.12
EBITD / Share (Annual)$0.43
Operating Margin (Annual)4.00%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)34.92x
ROI (5Y Avg)-1.26%
P/E Excl Extra (TTM)109.74x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.26
P/TBV (Quarterly)5.22x
P/B Ratio (Annual)5.14x
Inventory Turnover (TTM)4.05x
Pretax Margin (TTM)6.29%
Book Value / Share (Annual)$7.01
Price vs S&P 500 (13W)-7.29%
Net Margin Growth (5Y)20.74%
Beta1.20x
P/FCF (Annual)73.24x
Revenue / Share (TTM)$4.78
ROE (TTM)5.17%
52-Week Low$28.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.15
4.21
4.21
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VCELVericel Corporation | 6.56x | 16.45% | 74.42% | 38.88% | $35.81 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Vericel is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care in the U.S. market. Its portfolio includes MACI (autologous cultured chondrocytes) for cartilage repair, Epicel (cultured epidermal autografts) for burn treatment, and NexoBrid. The company handles the full value chain from research and development through manufacturing and distribution.